SG11201602175VA - Laquinimod combination therapy for treatment of multiple sclerosis - Google Patents

Laquinimod combination therapy for treatment of multiple sclerosis

Info

Publication number
SG11201602175VA
SG11201602175VA SG11201602175VA SG11201602175VA SG11201602175VA SG 11201602175V A SG11201602175V A SG 11201602175VA SG 11201602175V A SG11201602175V A SG 11201602175VA SG 11201602175V A SG11201602175V A SG 11201602175VA SG 11201602175V A SG11201602175V A SG 11201602175VA
Authority
SG
Singapore
Prior art keywords
treatment
multiple sclerosis
combination therapy
laquinimod
laquinimod combination
Prior art date
Application number
SG11201602175VA
Other languages
English (en)
Inventor
Volker Knappertz
Joel Kaye
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of SG11201602175VA publication Critical patent/SG11201602175VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
SG11201602175VA 2013-09-27 2014-09-26 Laquinimod combination therapy for treatment of multiple sclerosis SG11201602175VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361883698P 2013-09-27 2013-09-27
PCT/US2014/057705 WO2015065628A2 (en) 2013-09-27 2014-09-26 Laquinimod combination therapy for treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
SG11201602175VA true SG11201602175VA (en) 2016-04-28

Family

ID=52740749

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201602175VA SG11201602175VA (en) 2013-09-27 2014-09-26 Laquinimod combination therapy for treatment of multiple sclerosis

Country Status (16)

Country Link
US (3) US20150094332A1 (zh)
EP (1) EP3049075A4 (zh)
JP (1) JP2016533323A (zh)
KR (1) KR20160085757A (zh)
CN (1) CN105848653A (zh)
AR (1) AR097792A1 (zh)
AU (1) AU2014342917A1 (zh)
BR (1) BR112016006582A2 (zh)
CA (1) CA2925493A1 (zh)
EA (1) EA201690673A1 (zh)
IL (1) IL244620A0 (zh)
MX (1) MX2016003763A (zh)
SG (1) SG11201602175VA (zh)
TW (1) TW201601722A (zh)
UY (1) UY35748A (zh)
WO (1) WO2015065628A2 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2945978A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US20080227847A1 (en) * 2005-07-07 2008-09-18 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
AR061348A1 (es) * 2006-06-12 2008-08-20 Teva Pharma Preparados estables de laquinimod
ES2548999T3 (es) * 2009-06-19 2015-10-22 Teva Pharmaceutical Industries Ltd. Tratamiento de la esclerosis múltiple con laquinimod
CN105944081A (zh) * 2011-07-28 2016-09-21 泰华制药工业有限公司 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症

Also Published As

Publication number Publication date
IL244620A0 (en) 2016-04-21
AU2014342917A1 (en) 2016-04-21
AR097792A1 (es) 2016-04-13
EP3049075A2 (en) 2016-08-03
BR112016006582A2 (pt) 2017-08-01
US20170304253A1 (en) 2017-10-26
MX2016003763A (es) 2016-10-28
EA201690673A1 (ru) 2016-08-31
CA2925493A1 (en) 2015-05-07
UY35748A (es) 2015-04-30
KR20160085757A (ko) 2016-07-18
WO2015065628A3 (en) 2015-10-29
JP2016533323A (ja) 2016-10-27
US20160271094A1 (en) 2016-09-22
TW201601722A (zh) 2016-01-16
CN105848653A (zh) 2016-08-10
US20150094332A1 (en) 2015-04-02
EP3049075A4 (en) 2017-05-03
WO2015065628A2 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
HRP20180939T1 (hr) Kombinirana terapija za liječenje multiple skleroze
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
IL243976B (en) kdm1a inhibitors for disease treatment
IL252547A0 (en) Treatment of multiple sclerosis using laquinimod
HK1221408A1 (zh) 用於治療成膠質細胞瘤的組合療法
HK1213818A1 (zh) 依帕列淨的治療用途
LT3033086T (lt) Kombinuota terapija vėžiui gydyti
ZA201408820B (en) Use of high dose laquinimod for treating multiple sclerosis
HUE060721T2 (hu) Empagliflozin terápiás alkalmazásai
HK1218254A1 (zh) 用拉喹莫德治療多發性硬化症
EP2986294A4 (en) COMPOUNDS FOR THE TREATMENT OF PAIN
HK1225971A1 (zh) 使用拉喹莫德治療青光眼
IL244620A0 (en) A drug combination including laquinimod for the treatment of multiple sclerosis
HK1223854A1 (zh) 通過阿侖單抗誘導隨後通過拉喹莫德療法來治療多發性硬化症
EP2986295A4 (en) COMPOUNDS FOR THE TREATMENT OF PAIN
GB2525530B (en) Treatment of hard surfaces